$CATX
Perspective Therapeutics, Inc.

2013 Q2 Form 10-Q Financial Statement

#000114420413028975 Filed on May 15, 2013

View on sec.gov

Income Statement

Concept 2013 Q2 2013 Q1 2012 Q1
Revenue $1.240M $1.251M $1.317M
YoY Change -5.34% -5.0% -6.62%
Cost Of Revenue $1.100M $1.066M $1.113M
YoY Change 1.85% -4.27% 5.69%
Gross Profit $140.0K $185.9K $204.2K
YoY Change -39.13% -8.97% -42.86%
Gross Profit Margin 11.29% 14.85% 15.5%
Selling, General & Admin $980.0K $854.9K $834.8K
YoY Change -3.92% 2.4% -3.24%
% of Gross Profit 700.0% 459.85% 408.8%
Research & Development $180.0K $155.1K $132.2K
YoY Change -14.29% 17.32% -45.85%
% of Gross Profit 128.57% 83.45% 64.75%
Depreciation & Amortization $190.0K $180.0K $210.0K
YoY Change -26.92% -14.29% -47.5%
% of Gross Profit 135.71% 96.82% 102.83%
Operating Expenses $1.160M $1.010M $967.1K
YoY Change -0.85% 4.44% -7.97%
Operating Profit -$1.020M -$824.1K -$762.9K
YoY Change 8.51% 8.03% 10.01%
Interest Expense $30.00K $110.0K $210.0K
YoY Change -111.54% -47.62% -161.76%
% of Operating Profit
Other Income/Expense, Net $109.1K $210.0K
YoY Change -48.05% -162.34%
Pretax Income -$990.0K -$720.0K -$550.0K
YoY Change -17.5% 30.91% -46.6%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$990.0K -$715.0K -$552.9K
YoY Change -17.5% 29.33% -46.34%
Net Earnings / Revenue -79.84% -57.14% -41.97%
Basic Earnings Per Share
Diluted Earnings Per Share -$28.60K -$20.80K -$18.76K
COMMON SHARES
Basic Shares Outstanding 34.61M shares 34.61M
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q2 2013 Q1 2012 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.900M $3.680M $2.520M
YoY Change 8.61% 46.03% -5.62%
Cash & Equivalents $2.900M $3.684M $2.524M
Short-Term Investments
Other Short-Term Assets $26.69K $210.0K $170.0K
YoY Change 0.0% 23.53% -34.62%
Inventory $405.6K $357.0K $441.2K
Prepaid Expenses
Receivables $923.8K $830.0K $853.1K
Other Receivables $11.50K $10.00K $20.00K
Total Short-Term Assets $4.444M $5.092M $4.007M
YoY Change 7.43% 27.1% -12.33%
LONG-TERM ASSETS
Property, Plant & Equipment $1.684M $1.853M $2.592M
YoY Change -30.31% -28.5% -23.78%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $276.5K $293.6K $299.7K
YoY Change -8.35% -2.03% 57.71%
Total Long-Term Assets $2.612M $2.797M $3.584M
YoY Change -22.49% -21.94% -7.16%
TOTAL ASSETS
Total Short-Term Assets $4.444M $5.092M $4.007M
Total Long-Term Assets $2.612M $2.797M $3.584M
Total Assets $7.055M $7.890M $7.590M
YoY Change -6.0% 3.95% -9.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $430.0K $370.0K $350.0K
YoY Change 10.26% 5.71% 9.38%
Accrued Expenses $360.0K $280.0K $280.0K
YoY Change 38.46% 0.0% -9.68%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $792.9K $649.3K $626.1K
YoY Change 22.17% 3.7% -9.26%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $900.0K $910.0K $810.0K
YoY Change -13.46% 12.35% -7.95%
Total Long-Term Liabilities $900.0K $910.0K $810.0K
YoY Change -13.46% 12.35% -16.49%
TOTAL LIABILITIES
Total Short-Term Liabilities $792.9K $649.3K $626.1K
Total Long-Term Liabilities $900.0K $910.0K $810.0K
Total Liabilities $1.689M $1.555M $1.439M
YoY Change 0.11% 8.04% -12.77%
SHAREHOLDERS EQUITY
Retained Earnings -$52.09M -$51.10M -$47.03M
YoY Change 8.0% 8.65%
Common Stock $34.62K $34.61K $29.32K
YoY Change 11.85% 18.07%
Preferred Stock
YoY Change
Treasury Stock (at cost) $8.390K $8.390K $8.390K
YoY Change 0.0% 0.0%
Treasury Stock Shares 13.20K shares 13.20K shares 13.20K shares
Shareholders Equity $5.366M $6.335M $6.151M
YoY Change
Total Liabilities & Shareholders Equity $7.055M $7.890M $7.590M
YoY Change -6.0% 3.95% -9.96%

Cashflow Statement

Concept 2013 Q2 2013 Q1 2012 Q1
OPERATING ACTIVITIES
Net Income -$990.0K -$715.0K -$552.9K
YoY Change -17.5% 29.33% -46.34%
Depreciation, Depletion And Amortization $190.0K $180.0K $210.0K
YoY Change -26.92% -14.29% -47.5%
Cash From Operating Activities -$790.0K -$760.0K -$810.0K
YoY Change 25.4% -6.17% 55.77%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 -$40.00K
YoY Change -100.0% -100.0% -50.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00 -$40.00K
YoY Change -100.0% -100.0% -50.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 10.00K 0.000 0.000
YoY Change -98.73% -100.0%
NET CHANGE
Cash From Operating Activities -790.0K -760.0K -810.0K
Cash From Investing Activities 0.000 0.000 -40.00K
Cash From Financing Activities 10.00K 0.000 0.000
Net Change In Cash -780.0K -760.0K -850.0K
YoY Change -700.0% -10.59% 39.34%
FREE CASH FLOW
Cash From Operating Activities -$790.0K -$760.0K -$810.0K
Capital Expenditures $0.00 $0.00 -$40.00K
Free Cash Flow -$790.0K -$760.0K -$770.0K
YoY Change 31.67% -1.3% 75.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
dei Document Period End Date
DocumentPeriodEndDate
2013-03-31
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0000728387
CY2013Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
34611517 shares
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Entity Registrant Name
EntityRegistrantName
IsoRay, Inc.
dei Trading Symbol
TradingSymbol
ISR
isr Class Of Warrant Or Right Issued In Period Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightIssuedInPeriodExercisePriceOfWarrantsOrRights
0.6472
CY2012Q3 isr Gross Proceeds From Issuance Of Common Stock
GrossProceedsFromIssuanceOfCommonStock
3500000 USD
isr Issuance Of Common Stock In Connection With Warrant Exercises Net Of Issuance Costs Shares
IssuanceOfCommonStockInConnectionWithWarrantExercisesNetOfIssuanceCostsShares
2766 shares
isr Noncash Investing And Financing Activities Total
NoncashInvestingAndFinancingActivitiesTotal
USD
isr Noncash Investing And Financing Activities Total
NoncashInvestingAndFinancingActivitiesTotal
545511 USD
CY2012Q3 isr Payments Of Stock Issuance Costs Commission Expense
PaymentsOfStockIssuanceCostsCommissionExpense
87500 USD
CY2012Q3 isr Payments Of Stock Issuance Costs Legal And Accounting Expense
PaymentsOfStockIssuanceCostsLegalAndAccountingExpense
67306 USD
CY2012Q3 isr Payments Of Stock Issuance Costs Listing Expense
PaymentsOfStockIssuanceCostsListingExpense
47000 USD
CY2012Q3 isr Payments Of Stock Issuance Costs Other Expenses
PaymentsOfStockIssuanceCostsOtherExpenses
6217 USD
isr Provision For Reduction Of Doubtful Accounts
ProvisionForReductionOfDoubtfulAccounts
32174 USD
isr Provision For Reduction Of Doubtful Accounts
ProvisionForReductionOfDoubtfulAccounts
10256 USD
isr Supplemental Common Stock Warrant Liability
SupplementalCommonStockWarrantLiability
USD
isr Supplemental Common Stock Warrant Liability
SupplementalCommonStockWarrantLiability
484000 USD
CY2012Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
389105 USD
CY2013Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
367580 USD
CY2012Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
865056 USD
CY2013Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
830035 USD
CY2012Q2 us-gaap Accrued Vacation Current
AccruedVacationCurrent
88006 USD
CY2013Q1 us-gaap Accrued Vacation Current
AccruedVacationCurrent
100967 USD
CY2012Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
54030311 USD
CY2013Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
57406497 USD
us-gaap Adjustment For Amortization
AdjustmentForAmortization
21036 USD
us-gaap Adjustment For Amortization
AdjustmentForAmortization
26577 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
85369 USD
CY2012Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
33190 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
99568 USD
CY2013Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
27580 USD
CY2012Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
57604 USD
CY2013Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
25430 USD
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4328170 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4729833 shares
us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
50383 USD
us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
46062 USD
CY2012Q2 us-gaap Asset Retirement Obligations Noncurrent
AssetRetirementObligationsNoncurrent
724298 USD
CY2013Q1 us-gaap Asset Retirement Obligations Noncurrent
AssetRetirementObligationsNoncurrent
774681 USD
CY2012Q2 us-gaap Assets
Assets
7505482 USD
CY2013Q1 us-gaap Assets
Assets
7889963 USD
CY2012Q2 us-gaap Assets Current
AssetsCurrent
4136153 USD
CY2013Q1 us-gaap Assets Current
AssetsCurrent
5092490 USD
CY2012Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2672711 USD
CY2013Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3684214 USD
CY2011Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2112254 USD
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3436123 USD
CY2012Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2524397 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1011503 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
412143 USD
CY2012Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
1.38000
CY2013Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
1.3800
CY2012Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1959799 shares
CY2013Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1957033 shares
CY2012Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2012Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
193000000 shares
CY2013Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
193000000 shares
CY2012Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30950108 shares
CY2013Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34611517 shares
CY2012Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30950108 shares
CY2013Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34611517 shares
CY2012Q2 us-gaap Common Stock Value
CommonStockValue
30950 USD
CY2013Q1 us-gaap Common Stock Value
CommonStockValue
34612 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
3276314 USD
CY2012Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
1113151 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
3289982 USD
CY2013Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
1065574 USD
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
USD
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
61511 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
563850 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
643262 USD
CY2012Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
314000 USD
CY2013Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
131000 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
CY2012Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2013Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
65227 USD
us-gaap Description Of New Accounting Pronouncements Not Yet Adopted
DescriptionOfNewAccountingPronouncementsNotYetAdopted
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-BOTTOM: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0px" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top; TEXT-ALIGN: justify"> <td style="WIDTH: 0in">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 0.5in"><strong>2.</strong></td> <td style="TEXT-ALIGN: justify"><strong>New Accounting Pronouncements</strong></td> </tr> </table> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>&nbsp;</strong></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (the "FASB") or other standards setting bodies that are adopted by us as of the specified effective dates. Unless otherwise discussed, we believe the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial position, results of operations and cash flows upon adoption.</p> <!--EndFragment--></div> </div>
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
CY2012Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
119881 USD
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P8M27D
CY2013Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
82399 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1678487 USD
CY2012Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
575832 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1726017 USD
CY2013Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
564075 USD
us-gaap Gross Profit
GrossProfit
6853 USD
CY2012Q1 us-gaap Gross Profit
GrossProfit
204220 USD
us-gaap Gross Profit
GrossProfit
469461 USD
CY2013Q1 us-gaap Gross Profit
GrossProfit
185904 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-21525 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-26441 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-67195 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
50006 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-54654 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-54303 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-87368 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
161103 USD
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
27500 USD
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-11493 USD
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
36000 USD
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-68060 USD
us-gaap Increase Decrease In Other Employee Related Liabilities
IncreaseDecreaseInOtherEmployeeRelatedLiabilities
12961 USD
us-gaap Increase Decrease In Other Employee Related Liabilities
IncreaseDecreaseInOtherEmployeeRelatedLiabilities
12206 USD
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-2204 USD
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-406426 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
69427 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
13617 USD
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
104 USD
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
187 USD
us-gaap Interest And Debt Expense
InterestAndDebtExpense
6 USD
CY2012Q1 us-gaap Interest And Debt Expense
InterestAndDebtExpense
3266 USD
us-gaap Interest And Debt Expense
InterestAndDebtExpense
6323 USD
CY2013Q1 us-gaap Interest And Debt Expense
InterestAndDebtExpense
USD
CY2012Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
68386 USD
CY2013Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
45383 USD
CY2012Q2 us-gaap Inventory Net
InventoryNet
444345 USD
CY2013Q1 us-gaap Inventory Net
InventoryNet
356977 USD
CY2012Q2 us-gaap Inventory Noncurrent
InventoryNoncurrent
469758 USD
CY2013Q1 us-gaap Inventory Noncurrent
InventoryNoncurrent
469758 USD
CY2012Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
261835 USD
CY2013Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
103076 USD
CY2012Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
114124 USD
CY2013Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
208518 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
355 USD
CY2012Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
144 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
599 USD
CY2013Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
83 USD
CY2012Q2 us-gaap Liabilities
Liabilities
1687290 USD
CY2013Q1 us-gaap Liabilities
Liabilities
1554955 USD
CY2012Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7505482 USD
CY2013Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7889963 USD
CY2012Q2 us-gaap Liabilities Current
LiabilitiesCurrent
648992 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-13030 USD
CY2013Q1 us-gaap Liabilities Current
LiabilitiesCurrent
649274 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3294479 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2305449 USD
us-gaap Operating Expenses
OperatingExpenses
3126778 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2269946 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1824219 USD
CY2013Q1 us-gaap Operating Expenses
OperatingExpenses
1010024 USD
us-gaap Net Income Loss
NetIncomeLoss
-2863032 USD
CY2012Q1 us-gaap Net Income Loss
NetIncomeLoss
-552886 USD
us-gaap Net Income Loss
NetIncomeLoss
-2283946 USD
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-715037 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-3046381 USD
CY2012Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-762859 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-2657317 USD
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-824120 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-69087 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2871006 USD
CY2012Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-555544 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2291920 USD
CY2013Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-717695 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
183349 USD
CY2012Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
209973 USD
CY2013Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
27500 USD
CY2012Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
301691 USD
CY2013Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
293581 USD
CY2012Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
52000 USD
CY2013Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
88000 USD
CY2012Q2 us-gaap Other Receivables Gross Current
OtherReceivablesGrossCurrent
9925 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
373371 USD
CY2013Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
109083 USD
us-gaap Operating Expenses
OperatingExpenses
3053234 USD
CY2012Q1 us-gaap Operating Expenses
OperatingExpenses
967079 USD
CY2013Q1 us-gaap Other Receivables Gross Current
OtherReceivablesGrossCurrent
7721 USD
us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
10632 USD
us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
10632 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
12926 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
42900 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
26000 USD
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
7974 USD
CY2012Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
2658 USD
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
7974 USD
CY2013Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
2658 USD
CY2012Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2012Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7000000 shares
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
379095 USD
CY2013Q1 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
109000 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
3759443 USD
CY2013Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
1251478 USD
CY2013Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7000000 shares
CY2013Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-51097770 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
3283167 USD
CY2012Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
1317371 USD
CY2012Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
144116 USD
CY2013Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
213543 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3291977 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2274485 USD
CY2012Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3291977 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
11309 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1352 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1825 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
40244 USD
CY2012Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2416853 USD
CY2013Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1853003 USD
us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
USD
CY2012Q1 us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
USD
us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
50000 USD
CY2013Q1 us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
445785 USD
CY2012Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
132237 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
573212 USD
CY2013Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
155137 USD
CY2012Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
181027 USD
CY2013Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
181131 USD
CY2012Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-48234738 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
928962 USD
CY2012Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
259010 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
877549 USD
CY2013Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
290812 USD
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
1.87
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P4Y9M29D
CY2013Q1 us-gaap Treasury Stock Value
TreasuryStockValue
8390 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
183000 USD
CY2012Q1 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
213095 USD
us-gaap Share Based Compensation
ShareBasedCompensation
85369 USD
us-gaap Share Based Compensation
ShareBasedCompensation
99568 USD
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2037064 shares
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.93
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
13866 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2964 USD
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
149208 USD
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2312072 shares
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.82
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y10M17D
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
148708 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P4Y7M2D
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
135927 USD
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2221210 shares
CY2012Q2 us-gaap Stockholders Equity
StockholdersEquity
5818192 USD
CY2013Q1 us-gaap Stockholders Equity
StockholdersEquity
6335008 USD
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
31700 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
5200 shares
CY2012Q2 us-gaap Treasury Stock Shares
TreasuryStockShares
13200 shares
CY2013Q1 us-gaap Treasury Stock Shares
TreasuryStockShares
13200 shares
CY2012Q2 us-gaap Treasury Stock Value
TreasuryStockValue
8390 USD
CY2013Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
131000 USD
CY2011Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
484000 USD
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34359567 shares
CY2012Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29316306 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
28128125 shares
CY2013Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34611517 shares

Files In Submission

Name View Source Status
0001144204-13-028975-index-headers.html Edgar Link pending
0001144204-13-028975-index.html Edgar Link pending
0001144204-13-028975.txt Edgar Link pending
0001144204-13-028975-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
isr-20130331.xml Edgar Link completed
isr-20130331.xsd Edgar Link pending
isr-20130331_cal.xml Edgar Link unprocessable
isr-20130331_def.xml Edgar Link unprocessable
isr-20130331_lab.xml Edgar Link unprocessable
isr-20130331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v343705_10q.htm Edgar Link pending
v343705_ex31-1.htm Edgar Link pending
v343705_ex31-2.htm Edgar Link pending
v343705_ex32.htm Edgar Link pending